Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction

Study shows Kowa’s novel synthetic statin is safe and well tolerated in combination with warfarin

13.06.2009

Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction Study shows Kowa's novel synthetic statin is safe and well tolerated in combination with warfarin [EUROPE]

BOSTON, June 15, 2009 - New data presented today showed that pitavastatin may provide a new treatment option for patients with dyslipidaemia and complex issues, such as those on multiple medications, as evidenced by a study supporting pitavastatin's potential for low drug-drug interaction. The data were presented today by Kowa at the XV International Symposium on Atherosclerosis in Boston.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X